University of California San Francisco
San Francisco, California, 94143, United States
NCT Number: NCT05021172
This clinical trial assesses the feasibility and acceptability of a smarter screening intervention for breast and colorectal cancer in older adults. This study aims to learn more about how to support patients and physicians in making cancer screening decisions for older adults.
Looking for future studies?
Notify Me70 year and older
All sexes
Interventional
Not applicable
San Francisco, California, 94143, United States
PRIMARY OBJECTIVES:
I. Complete development of and refine "Smarter Screening", a multi-component, patient-centered intervention centered around ePrognosis: Cancer Screening to facilitate shared decision-making screening discussions for breast and colorectal cancer in older adults.
II. Assess feasibility and acceptability of the "Smarter Screening" intervention and assess its impact versus usual care on shared decision-making about whether or not to continue breast and colorectal cancer (CRC) screening among multi-ethnic and socioeconomically diverse primary care patients.
EXPLORATORY OBJECTIVES:
I. Impact on breast and CRC screening versus usual care.
II. Risk perception, worry, and a patient-reported measure of decision quality.
OUTLINE: Participants are randomized to 1 of 2 arms.
ARM I: Participants receive Passport to Health booklet and complete ePrognosis before scheduled primary care visit.
ARM II: Participants receive usual care before scheduled primary care visit.
After completion of study, participants are followed up at 1 week post primary care visit.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Receive usual care
Other names: standard of care, standard therapy
Receive Passport to Health booklet
Complete ePrognosis
Ancillary studies
Time frame: 6 months
Ability to successfully recruit the target of approximately 40 patients will be determined by the overall number of participants who were screened for enrollment compared to the overall number of participants who were randomized to one of the groups.
Time frame: 6 months
Ability to successfully recruit PCPs will be determined by the overall number of physicians who were contacted compared to the overall number of physicians who actively participated over the course of the study.
Time frame: 6 months
The investigators aim to attain at least 75% of recruited patients in each arm at the 6 month follow-up.
Time frame: 6 months
The proportion of participants who received an ePrognosis report will be reported
Time frame: 6 months
All enrolled intervention PCPs will receive a web-based survey after each patient visit to record whether the physicians used and/or discussed ePrognosis in that visit. The proportion of physicians who use the ePrognosis clinician report in their cancer screening counseling with participants/patients will be reported
Time frame: 6 months
A survey will be provided to PCPs and used to measure acceptability of the ePrognosis report by asking patients and providers to provide feedback about the intervention, including likes and dislikes, and future recommendation of using the report provided.
Time frame: 6 months
The impact on breast cancer screening versus usual care will be measured by comparing the proportion or participants who were screened for cancers by treatment arm.
Time frame: 6 months
The impact on colorectal cancer screening versus usual care will be measured by comparing the proportion or participants who were screened for cancers by treatment arm.
University of California, San Francisco
Other
Incorporating ePrognosis to Encourage "Smarter Screening" for Breast and Colorectal Cancer in Older Adults
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04081779
Breast Carcinoma, Breast Diseases
Seattle, Washington, United States
View Trial DetailsNCT03630354
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Portland, Oregon, United States
View Trial DetailsNCT02408406
Bladder Carcinoma, Breast Carcinoma
Duarte, California, United States
View Trial DetailsNCT00179348
Alopecia, Anxiety
The Bronx, New York, United States
View Trial Details